CAT-2003 / Astria Therap - LARVOL DELTA

Arid1a loss drives non-alcoholic steatohepatitis in mice via epigenetic dysregulation of hepatic lipogenesis and fatty acid oxidation. (PubMed, Hepatology) - "Inhibition of lipogenesis using CAT-2003, a potent sterol regulatory element-binding protein inhibitor, mediated improvements in markers of fatty liver disease progression in this Arid1a/Pten double knockout model. ARID1A plays a role in the epigenetic regulation of hepatic lipid homeostasis, and its suppression contributes to fatty liver pathogenesis. Combined Arid1a and Pten deletion shows accelerated fatty liver disease progression and is a useful mouse model for studying new therapeutic strategies for NASH."

Journal • Fibrosis • Gastrointestinal Cancer • Hepatocellular Cancer • Hepatology • Immunology • Non-alcoholic Fatty Liver Disease • Non-alcoholic Steatohepatitis • Oncology • Solid Tumor

Pilot Study To Assess CAT-2003 in Patients With Chylomicronemia (clinicaltrials.gov) - P2; N=13; Completed; Sponsor: Catabasis Pharmaceuticals; Active, not recruiting -> Completed

Trial completion • Biosimilar • Dyslipidemia • Hemophilia

Catabasis to present phase 1 data from Oral SMART linker conjugate CAT-2003 at Upcoming Conference (Catabasis Press Release) - “...new clinical data on the inhibition of PCSK9* by its oral SMART Linker conjugate, CAT-2003, will be presented at the Physicians Academy for Continuing Education (PACE) conference in Amsterdam on Aug. 31...The presentation will include results from CAT-2003’s recently completed Phase 1 trial.”

Anticipated conference • Anticipated P1 data • Atherosclerosis • Dyslipidemia